Becton, Dickinson and Company

NYSE:BDX Stock Report

Market Cap: US$67.9b

Becton Dickinson Valuation

Is BDX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BDX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BDX ($234.45) is trading below our estimate of fair value ($367.76)

Significantly Below Fair Value: BDX is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BDX?

Other financial metrics that can be useful for relative valuation.

BDX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.2x
Enterprise Value/EBITDA16.3x
PEG Ratio2.7x

Price to Earnings Ratio vs Peers

How does BDX's PE Ratio compare to its peers?

The above table shows the PE ratio for BDX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average34.6x
EW Edwards Lifesciences
38.4x9.8%US$54.4b
MDT Medtronic
27.1x9.7%US$113.9b
IDXX IDEXX Laboratories
49.4x9.9%US$42.8b
GEHC GE HealthCare Technologies
23.4x13.0%US$37.4b
BDX Becton Dickinson
49.7x18.1%US$67.9b

Price-To-Earnings vs Peers: BDX is expensive based on its Price-To-Earnings Ratio (49.7x) compared to the peer average (34.6x).


Price to Earnings Ratio vs Industry

How does BDX's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.6%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.6%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: BDX is expensive based on its Price-To-Earnings Ratio (49.7x) compared to the US Medical Equipment industry average (38x).


Price to Earnings Ratio vs Fair Ratio

What is BDX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BDX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio49.7x
Fair PE Ratio38.3x

Price-To-Earnings vs Fair Ratio: BDX is expensive based on its Price-To-Earnings Ratio (49.7x) compared to the estimated Fair Price-To-Earnings Ratio (38.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BDX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$234.45
US$279.00
+19.0%
8.3%US$325.00US$240.00n/a15
May ’25US$233.72
US$278.96
+19.4%
8.2%US$325.00US$240.00n/a14
Apr ’25US$244.05
US$281.86
+15.5%
7.6%US$325.00US$240.00n/a14
Mar ’25US$235.31
US$283.07
+20.3%
7.5%US$325.00US$240.00n/a15
Feb ’25US$242.35
US$285.47
+17.8%
7.4%US$325.00US$240.00n/a15
Jan ’25US$243.83
US$284.07
+16.5%
7.5%US$325.00US$240.00n/a15
Dec ’24US$238.25
US$286.07
+20.1%
7.7%US$325.00US$240.00n/a15
Nov ’24US$253.78
US$301.27
+18.7%
5.2%US$325.00US$271.00n/a15
Oct ’24US$258.53
US$301.67
+16.7%
5.2%US$325.00US$271.00n/a15
Sep ’24US$278.46
US$300.43
+7.9%
5.3%US$325.00US$271.00n/a16
Aug ’24US$278.54
US$291.93
+4.8%
6.5%US$325.00US$260.00n/a16
Jul ’24US$264.01
US$286.39
+8.5%
4.8%US$306.00US$260.00n/a15
Jun ’24US$248.11
US$285.73
+15.2%
4.9%US$306.00US$260.00n/a15
May ’24US$265.32
US$278.87
+5.1%
6.8%US$306.00US$245.00US$233.7215
Apr ’24US$247.54
US$276.46
+11.7%
6.7%US$306.00US$245.00US$244.0513
Mar ’24US$232.16
US$276.46
+19.1%
6.7%US$306.00US$245.00US$235.3113
Feb ’24US$254.17
US$272.15
+7.1%
6.6%US$306.00US$245.00US$242.3513
Jan ’24US$254.30
US$268.00
+5.4%
6.5%US$306.00US$245.00US$243.8313
Dec ’23US$250.83
US$264.42
+5.4%
8.1%US$306.00US$220.00US$238.2512
Nov ’23US$233.88
US$277.67
+18.7%
8.1%US$319.00US$227.00US$253.7812
Oct ’23US$222.83
US$278.08
+24.8%
7.6%US$319.00US$235.00US$258.5312
Sep ’23US$255.25
US$278.08
+8.9%
7.6%US$319.00US$235.00US$278.4612
Aug ’23US$244.77
US$273.42
+11.7%
6.4%US$306.00US$235.00US$278.5412
Jul ’23US$251.80
US$280.50
+11.4%
5.2%US$306.00US$255.00US$264.0112
Jun ’23US$251.40
US$282.92
+12.5%
6.0%US$310.00US$255.00US$248.1112
May ’23US$247.19
US$288.70
+16.8%
5.9%US$318.00US$260.00US$265.3213

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.